Category: Biotechnology

BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2384849 NEW YORK, Jan. 25, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that Chaim Lebovits, CEO will provide a corporate overview presentation at

Basilea Announces Collaboration to Study Derazantinib & Atezolizumab (Tecentriq®) in Urothelial Cancer

From Startup ARQULE Link to Full Article: BURLINGTON, Mass.–(BUSINESS WIRE)–Jan. 24, 2019– ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (Tecentriq®), in

BrainStorm Granted Additional Patent for NurOwn® in Israel

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2384331 NEW YORK, Jan. 22, 2019 (GLOBE NEWSWIRE) — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for debilitating neurodegenerative diseases, today announced that the Israel Patent Office has granted an additional patent titled “Methods

Metabolon appoints Michael Rasche as President of International Business

From Startup Metabolon Link to Full Article: https://www.metabolon.com/who-we-are/news-events/news/metabolon-appoints-michael-rasche-president-international-business RALEIGH, NC USA and POTSDAM GERMANY – January 21, 2019   Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a

AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis

From Startup Avrobio Link to Full Article: Phase 1/2 study to be led by team at University of California, San Diego, with rights licensed to AVROBIO CAMBRIDGE, Mass., Jan. 18, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that

AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019

From Startup Avrobio Link to Full Article: Analyst and Investor Event to be Webcast on Wednesday, February 6, 2019 at 6:30 p.m. ET CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) — AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates

Anika Announces Plans to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Summit in San Diego

From Startup Anika Therapeutics Link to Full Article: http://ir.anikatherapeutics.com/news-releases/news-release-details/anika-announces-plans-showcase-hyalofast-international-cartilage BEDFORD, Mass.–(BUSINESS WIRE)–Jan. 16, 2019– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase HYALOFAST, a biodegradable, HA-based cartilage repair scaffold,

Precision BioSciences Announces Formation of Scientific Advisory Board With Anderson, Kantarjian, Schinazi and Turtle

From Startup Precision Biosciences Link to Full Article: http://precisionbiosciences.com/precision-biosciences-announces-formation-of-scientific-advisory-board/ DURHAM, North Carolina, USA, January 16, 2019 – Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, MD, Hagop Kantarjian, MD, Raymond Schinazi, PhD, DSc, and Cameron Turtle, MBBS, PhD. Drs. Anderson, Kantarjian,

Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Treatment for Hyperammonemia

From Startup Synlogic Tx Link to Full Article: –Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan.